Vertex Pharmaceuticals Incorporated Company Profile (NASDAQ:VRTX)

About Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated logoVertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:VRTX
  • CUSIP: 92532F10
  • Web: www.vrtx.com
Capitalization:
  • Market Cap: $29.87 billion
  • Outstanding Shares: 249,068,000
Average Prices:
  • 50 Day Moving Avg: $116.53
  • 200 Day Moving Avg: $94.15
  • 52 Week Range: $71.46 - $121.96
P/E:
  • Trailing P/E Ratio: 167.25
  • Foreward P/E Ratio: 38.44
  • P/E Growth: 1.12
Sales & Book Value:
  • Annual Revenue: $2.02 billion
  • Price / Sales: 14.79
  • Book Value: $6.03 per share
  • Price / Book: 19.89
Profitability:
  • EBIDTA: $356.32 million
  • Net Margins: -6.76%
  • Return on Equity: -2.15%
  • Return on Assets: -0.98%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 2.08%
  • Quick Ratio: 1.98%
Misc:
  • Average Volume: 1.91 million shs.
  • Beta: 0.79
  • Short Ratio: 3.45
 

Frequently Asked Questions for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

What is Vertex Pharmaceuticals Incorporated's stock symbol?

Vertex Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "VRTX."

How were Vertex Pharmaceuticals Incorporated's earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its quarterly earnings results on Thursday, April, 27th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.04 by $0.09. The company earned $714.72 million during the quarter, compared to the consensus estimate of $692.64 million. Vertex Pharmaceuticals Incorporated had a negative return on equity of 2.15% and a negative net margin of 6.76%. Vertex Pharmaceuticals Incorporated's revenue for the quarter was up 79.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.09 earnings per share. View Vertex Pharmaceuticals Incorporated's Earnings History.

When will Vertex Pharmaceuticals Incorporated make its next earnings announcement?

Vertex Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Tuesday, July, 25th 2017. View Earnings Estimates for Vertex Pharmaceuticals Incorporated.

Where is Vertex Pharmaceuticals Incorporated's stock going? Where will Vertex Pharmaceuticals Incorporated's stock price be in 2017?

23 brokers have issued twelve-month target prices for Vertex Pharmaceuticals Incorporated's stock. Their predictions range from $75.00 to $153.00. On average, they expect Vertex Pharmaceuticals Incorporated's share price to reach $114.44 in the next twelve months. View Analyst Ratings for Vertex Pharmaceuticals Incorporated.

What are analysts saying about Vertex Pharmaceuticals Incorporated stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals Incorporated stock:

  • 1. Needham & Company LLC analysts commented, "Vertex announced 1Q17 financial results last night. Orkambi WW sales $295M beat our $277.5M and consensus $280M ests. Kalydeco WW sales $186M beat our $178.0M and consensus $175M ests. Mgmt raised Kalydeco, but left unch Orkambi guidance ($1.1-1.3B Orkambi and $710M-$730M from $690-710M Kalydeco). Orkambi driven by strong uptake and compliance in pediatric pts and Kalydeco driven by one time reimbursement in Europe. Our 2Q17 Orkambi and Kalydeco ests are $294.0M (was $287.5M) and $179.0M (was $178.0M). Stock reflects IVA/ TEZ commercial success and we maintain HOLD." (4/28/2017)
  • 2. Maxim Group analysts commented, "Vertex reported 1Q17 with total CF revenue of $481M, which was above consensus of $444M, driven by both Orkambi and Kalydeco revenues beating estimates." (4/28/2017)
  • 3. According to Zacks Investment Research, "Vertex has two cystic fibrosis (CF) CF drugs – Kalydeco & Orkambi – in its portfolio with blockbuster potential. However, Vertex has faced many challenges with respect to commercialization of Orkambi in ex-U.S. markets. We believe the 2017 Orkambi revenue guidance is below expectations and dependent on reimbursement discussions in Europe. However, Vertex’s CF pipeline is quite strong.  Investor focus will now be on the triple combination CF regimens which are crucial for long-term growth at Vertex. Although the stock declined in 2016, it has done well this year.  Recently, positive data from two late-stage trials evaluating a combination of tezacaftor and Kalydeco pushed up the shares. Estimates have also gone up lately ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in recent quarters. " (4/12/2017)
  • 4. BMO Capital Markets analysts commented, "We believe Vertex's acquisition of Concert's CTP-656, a deuterated ivacaftor (Kalydeco), removes a key potential competitor in the cystic fibrosis space. In addition, CTP-656 could replace Kalydeco in the triple combo, allowing a once-daily (QD) regimen, which would offset an important advaVertex Pharma (NASDAQ: VRTX)ntage of Galapagos's QD triple combo in development. We also believe CTP-656's later patent expiration date (2032 vs. 2027 for Kalydeco) will be an important lifecycle management component of Vertex's cystic fibrosis franchise." (3/7/2017)
  • 5. Robert W. Baird analysts commented, "Vertex announced plans to acquire Concert Pharmaceuticals' CTP-656, or deuterated ivacaftor. We think this acquisition highlights Vertex's commitment to defending its position as the leading CF company as it both eliminates a potential competitor and allows access to a once-daily modified version of ivacaftor with a longer patent life than ivacaftor itself. Overall, we think this is a smart deal for the company at a reasonable price, and reiterate our Outperform rating." (3/6/2017)

Who are some of Vertex Pharmaceuticals Incorporated's key competitors?

Who are Vertex Pharmaceuticals Incorporated's key executives?

Vertex Pharmaceuticals Incorporated's management team includes the folowing people:

  • Jeffrey M. Leiden M.D., Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Ian F. Smith CPA, Chief Financial Officer, Chief Operating Officer, Executive Vice President
  • Michael J. Parini J.D., Executive Vice President, Chief Legal and Administrative Officer
  • David Altshuler M.D., Ph.D., Executive Vice President - Global Research, Chief Scientific Officer
  • Stuart A. Arbuckle, Executive Vice President, Chief Commercial Officer
  • Jeffrey A. Chodakewitz M.D., Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
  • Amit K. Sachdev J.D., Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
  • Paul M. Silva, Senior Vice President, Corporate Controller
  • Elaine S. Ullian, Co-Lead Independent Director
  • Sangeeta N. Bhatia M.D., Ph.D., Independent Director

Who owns Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.73%), FMR LLC (7.57%), Vanguard Group Inc. (6.61%), State Street Corp (4.82%), Ameriprise Financial Inc. (3.31%) and Waddell & Reed Financial Inc. (1.46%). Company insiders that own Vertex Pharmaceuticals Incorporated stock include Amit Sachdev, David Altshuler, Elaine Ullian, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Paul M Silva, Stuart A Arbuckle and Yuchun Lee. View Institutional Ownership Trends for Vertex Pharmaceuticals Incorporated.

Who sold Vertex Pharmaceuticals Incorporated stock? Who is selling Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Asset Management Americas Inc., Thrivent Financial For Lutherans, Point72 Asset Management L.P., Ameriprise Financial Inc., Manning & Napier Advisors LLC, AXA and Lazard Asset Management LLC. Company insiders that have sold Vertex Pharmaceuticals Incorporated stock in the last year include Amit Sachdev, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Paul M Silva and Stuart A Arbuckle. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

Who bought Vertex Pharmaceuticals Incorporated stock? Who is buying Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Westfield Capital Management Co. LP, Morgan Stanley, TIAA CREF Investment Management LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

How do I buy Vertex Pharmaceuticals Incorporated stock?

Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vertex Pharmaceuticals Incorporated's stock price today?

One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $119.92.


MarketBeat Community Rating for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  858 (Vote Outperform)
Underperform Votes:  456 (Vote Underperform)
Total Votes:  1,314
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (?)
Ratings Breakdown: 9 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.61)
Consensus Price Target: $114.44 (4.57% downside)

Analysts' Ratings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017Maxim GroupSet Price TargetBuy$143.00LowView Rating Details
5/19/2017JMP SecuritiesReiterated RatingOutperform$125.00 -> $127.00LowView Rating Details
5/19/2017Bank of America CorpReiterated RatingNeutral$121.00 -> $125.00LowView Rating Details
5/19/2017Morgan StanleyReiterated RatingOverweight$150.00 -> $153.00LowView Rating Details
5/2/2017Jefferies Group LLCReiterated RatingBuy$126.00HighView Rating Details
4/30/2017Oppenheimer Holdings Inc.Reiterated RatingHoldLowView Rating Details
4/28/2017Needham & Company LLCReiterated RatingHoldLowView Rating Details
4/28/2017Robert W. BairdBoost Price TargetOutperform$115.00 -> $136.00LowView Rating Details
4/28/2017Credit Suisse Group AGBoost Price TargetOutperform$108.00 -> $125.00LowView Rating Details
4/23/2017Barclays PLCReiterated RatingEqual Weight$90.00 -> $100.00LowView Rating Details
4/2/2017HC WainwrightReiterated RatingNeutral$85.00LowView Rating Details
3/30/2017Cowen and CompanyReiterated RatingMarket Perform$75.00LowView Rating Details
3/29/2017Citigroup IncBoost Price TargetBuy$105.00 -> $124.00LowView Rating Details
3/29/2017Stifel NicolausBoost Price TargetBuy$100.00 -> $129.00HighView Rating Details
3/29/2017BMO Capital MarketsUpgradeMarket Perform -> Outperform$89.67 -> $100.00HighView Rating Details
3/20/2017Leerink SwannReiterated RatingOutperformMediumView Rating Details
3/14/2017ArgusReiterated RatingBuy$115.00 -> $92.95LowView Rating Details
1/3/2017JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
12/25/2016Piper Jaffray CompaniesSet Price TargetBuy$129.00N/AView Rating Details
12/7/2016Janney Montgomery ScottReiterated RatingNeutral$98.00N/AView Rating Details
11/1/2016William BlairDowngradeOutperform -> Market Perform$105.00 -> $81.00N/AView Rating Details
10/12/2016Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
9/13/2016Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
4/28/2016Goldman Sachs Group IncDowngradeBuy -> Neutral$109.00 -> $88.00N/AView Rating Details
3/28/2016GuggenheimLower Price TargetBuy$145.00 -> $114.00N/AView Rating Details
9/15/2015NomuraInitiated CoverageBuy$162.00N/AView Rating Details
7/31/2015Deutsche Bank AGReiterated RatingBuy$155.00N/AView Rating Details
7/7/2015BTIG ResearchLower Price TargetBuy$200.00 -> $180.00N/AView Rating Details
6/5/2015Canaccord GenuityReiterated RatingBuy$150.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Earnings by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Earnings History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2017        
4/27/2017Q1 2017$0.04$0.13$692.64 million$714.72 millionViewN/AView Earnings Details
1/25/2017Q4 2016$0.29$0.35$453.40 million$458.71 millionViewN/AView Earnings Details
10/25/2016Q316$0.18$0.16$423.53 million$413.78 millionViewListenView Earnings Details
7/27/2016Q216$0.21$0.24$428.08 million$431.61 millionViewListenView Earnings Details
4/27/2016Q116$0.29$0.09$439.94 million$398.10 millionViewListenView Earnings Details
1/27/2016Q4$0.17$0.17$406.30 million$417.94 millionViewListenView Earnings Details
10/28/2015Q315($0.60)($0.13)$245.84 million$309.82 millionViewListenView Earnings Details
7/29/2015Q215($0.58)($0.54)$149.49 million$166.00 millionViewListenView Earnings Details
4/29/2015Q115($0.75)($0.62)$142.38 million$138.51 millionViewListenView Earnings Details
1/28/2015Q414($0.65)($0.55)$137.50 million$144.56 millionViewListenView Earnings Details
10/28/2014Q314($0.62)($0.37)$146.20 million$179.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.71)($0.61)$131.85 million$138.42 millionViewListenView Earnings Details
5/1/2014Q114($0.68)($0.65)$134.46 million$118.50 millionViewN/AView Earnings Details
1/29/2014Q413($0.49)($0.56)$221.08 million$351.20 millionViewListenView Earnings Details
10/29/2013Q413($0.33)($0.32)$278.80 million$222.00 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.18)($0.26)$308.02 million$310.80 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)$0.03$307.85 million$328.40 millionViewN/AView Earnings Details
1/29/2013Q4 2012($0.07)($0.35)$318.53 million$334.00 millionViewN/AView Earnings Details
11/1/2012Q312$0.34$0.13$377.14 million$336.00 millionViewN/AView Earnings Details
7/30/2012$0.68$0.46ViewN/AView Earnings Details
4/26/2012$0.57$0.43ViewN/AView Earnings Details
2/2/2012$0.76$0.74ViewN/AView Earnings Details
10/27/2011$0.17$0.70ViewN/AView Earnings Details
7/28/2011($1.00)($0.67)ViewN/AView Earnings Details
5/3/2011($1.09)($0.91)ViewN/AView Earnings Details
2/3/2011($0.93)($0.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
2017 EPS Consensus Estimate: $0.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.02)$0.04$0.02
Q2 20174$0.02$0.47$0.16
Q3 20173$0.08$0.15$0.11
Q4 20173$0.12$0.33$0.24
(Data provided by Zacks Investment Research)

Dividends

Dividend History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/29/2013quarterly$0.402/20/20133/13/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Insider Ownership Percentage: 1.90%
Institutional Ownership Percentage: 94.85%
Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Institutional Ownership by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/2/2017Jeffrey ChodakewitzCMOSell8,979$121.05$1,086,907.95View SEC Filing  
4/28/2017Jeffrey M LeidenCEOSell157,200$119.50$18,785,400.00View SEC Filing  
4/5/2017Jeffrey ChodakewitzCMOSell8,021$114.00$914,394.00View SEC Filing  
4/3/2017Jeffrey ChodakewitzCMOSell2,291$108.85$249,375.35View SEC Filing  
3/29/2017Amit SachdevEVPSell80,500$107.63$8,664,215.00View SEC Filing  
3/29/2017Jeffrey ChodakewitzCMOSell13,750$106.65$1,466,437.50View SEC Filing  
3/29/2017Paul M SilvaSVPSell1,688$106.30$179,434.40View SEC Filing  
1/11/2017Joshua S BogerDirectorSell8,000$82.48$659,840.00View SEC Filing  
1/4/2017Joshua S BogerDirectorSell6,500$77.13$501,345.00View SEC Filing  
12/29/2016Joshua S BogerDirectorSell6,500$74.33$483,145.00View SEC Filing  
12/21/2016Joshua S BogerDirectorSell6,500$74.16$482,040.00View SEC Filing  
12/14/2016Joshua S BogerDirectorSell6,500$77.52$503,880.00View SEC Filing  
11/30/2016Joshua S BogerDirectorSell6,500$83.48$542,620.00View SEC Filing  
11/23/2016Joshua S BogerDirectorSell6,500$86.47$562,055.00View SEC Filing  
11/16/2016Joshua S BogerDirectorSell6,500$91.55$595,075.00View SEC Filing  
11/10/2016Paul M SilvaSVPSell5,062$90.98$460,540.76View SEC Filing  
11/9/2016Joshua S BogerDirectorSell6,500$90.98$591,370.00View SEC Filing  
11/9/2016Stuart A ArbuckleEVPSell1,208$90.00$108,720.00View SEC Filing  
11/2/2016Joshua S BogerDirectorSell6,500$77.75$505,375.00View SEC Filing  
10/26/2016Joshua S BogerDirectorSell6,500$79.26$515,190.00View SEC Filing  
10/19/2016Joshua S BogerDirectorSell6,500$81.84$531,960.00View SEC Filing  
10/12/2016Joshua S BogerDirectorSell6,500$81.14$527,410.00View SEC Filing  
10/5/2016Joshua S BogerDirectorSell6,500$87.44$568,360.00View SEC Filing  
10/3/2016Stuart A ArbuckleEVPSell1,208$86.46$104,443.68View SEC Filing  
9/28/2016Joshua S BogerDirectorSell6,500$88.15$572,975.00View SEC Filing  
9/21/2016Joshua S BogerDirectorSell6,500$90.82$590,330.00View SEC Filing  
9/14/2016Joshua S BogerDirectorSell6,500$92.37$600,405.00View SEC Filing  
9/7/2016Joshua S BogerDirectorSell6,500$95.66$621,790.00View SEC Filing  
8/31/2016Joshua S BogerDirectorSell6,500$94.62$615,030.00View SEC Filing  
8/24/2016Joshua S BogerDirectorSell7,500$100.46$753,450.00View SEC Filing  
8/22/2016Joshua S BogerDirectorSell1,100$100.79$110,869.00View SEC Filing  
8/17/2016Joshua S BogerDirectorSell6,900$99.63$687,447.00View SEC Filing  
8/11/2016Joshua S BogerDirectorSell900$100.19$90,171.00View SEC Filing  
8/10/2016Joshua S BogerDirectorSell7,100$100.24$711,704.00View SEC Filing  
8/3/2016Joshua S BogerDirectorSell47,000$100.66$4,731,020.00View SEC Filing  
7/27/2016Joshua S BogerDirectorSell6,500$95.93$623,545.00View SEC Filing  
7/20/2016Joshua S BogerDirectorSell6,500$90.33$587,145.00View SEC Filing  
7/13/2016Joshua S BogerDirectorSell6,500$88.81$577,265.00View SEC Filing  
7/6/2016Joshua S BogerDirectorSell5,140$88.99$457,408.60View SEC Filing  
6/29/2016Joshua S BogerDirectorSell5,130$84.82$435,126.60View SEC Filing  
6/22/2016Joshua S BogerDirectorSell5,130$86.61$444,309.30View SEC Filing  
6/15/2016Joshua S BogerDirectorSell5,130$91.18$467,753.40View SEC Filing  
6/8/2016Joshua S BogerDirectorSell5,130$94.95$487,093.50View SEC Filing  
6/1/2016Joshua S BogerDirectorSell5,130$93.65$480,424.50View SEC Filing  
5/25/2016Joshua S BogerDirectorSell5,130$89.09$457,031.70View SEC Filing  
5/18/2016Joshua S BogerDirectorSell5,130$81.18$416,453.40View SEC Filing  
5/16/2016Amit SachdevEVPSell117$81.67$9,555.39View SEC Filing  
5/16/2016Ian F SmithCFOSell202$82.06$16,576.12View SEC Filing  
5/11/2016Joshua S BogerDirectorSell5,130$86.50$443,745.00View SEC Filing  
5/9/2016Paul M SilvaSVPSell3,000$87.63$262,890.00View SEC Filing  
5/4/2016Joshua S BogerDirectorSell5,130$81.02$415,632.60View SEC Filing  
4/27/2016Joshua S BogerDirectorSell5,130$83.67$429,227.10View SEC Filing  
4/20/2016Joshua S BogerDirectorSell5,130$84.10$431,433.00View SEC Filing  
4/13/2016Joshua S BogerDirectorSell5,130$84.27$432,305.10View SEC Filing  
4/6/2016Joshua S BogerDirectorSell5,130$89.56$459,442.80View SEC Filing  
3/30/2016Joshua S BogerDirectorSell5,130$78.83$404,397.90View SEC Filing  
3/23/2016Joshua S BogerDirectorSell5,130$81.38$417,479.40View SEC Filing  
3/16/2016Joshua S BogerDirectorSell5,130$79.65$408,604.50View SEC Filing  
3/2/2016Joshua S BogerDirectorSell5,130$91.80$470,934.00View SEC Filing  
2/24/2016Joshua S BogerDirectorSell5,130$85.25$437,332.50View SEC Filing  
2/17/2016Joshua S. BogerDirectorSell5,130$86.93$445,950.90View SEC Filing  
2/10/2016Joshua S. BogerDirectorSell5,130$82.57$423,584.10View SEC Filing  
2/3/2016Ian F. SmithCFOSell12,084$90.84$1,097,710.56View SEC Filing  
2/3/2016Jeffrey M. LeidenCEOSell9,834$90.82$893,123.88View SEC Filing  
2/3/2016Joshua S. BogerDirectorSell5,130$90.81$465,855.30View SEC Filing  
2/3/2016Paul M. SilvaSVPSell5,062$90.82$459,730.84View SEC Filing  
2/3/2016Stuart A. ArbuckleEVPSell6,042$90.82$548,734.44View SEC Filing  
2/2/2016Jeffrey ChodakewitzCMOSell2,375$91.38$217,027.50View SEC Filing  
1/27/2016Joshua S. BogerDirectorSell11,200$93.22$1,044,064.00View SEC Filing  
1/20/2016Joshua S. BogerDirectorSell10,400$93.69$974,376.00View SEC Filing  
1/13/2016Joshua S. BogerDirectorSell10,400$98.41$1,023,464.00View SEC Filing  
1/6/2016Joshua S. BogerDirectorSell10,400$121.96$1,268,384.00View SEC Filing  
1/4/2016Yuchun LeeDirectorSell1,125$122.21$137,486.25View SEC Filing  
12/30/2015Joshua S. BogerDirectorSell10,400$127.15$1,322,360.00View SEC Filing  
12/21/2015Joshua S. BogerDirectorSell10,400$119.26$1,240,304.00View SEC Filing  
12/9/2015Joshua S. BogerDirectorSell10,400$120.80$1,256,320.00View SEC Filing  
12/4/2015Stuart A. ArbuckleEVPSell4,531$123.98$561,753.38View SEC Filing  
12/2/2015Joshua S. BogerDirectorSell10,400$130.91$1,361,464.00View SEC Filing  
12/1/2015David AltshulerEVPSell5,000$131.00$655,000.00View SEC Filing  
12/1/2015Yuchun LeeDirectorSell1,125$129.65$145,856.25View SEC Filing  
11/23/2015Joshua S. BogerDirectorSell10,400$132.18$1,374,672.00View SEC Filing  
11/11/2015Joshua S. BogerDirectorSell10,400$118.59$1,233,336.00View SEC Filing  
11/4/2015Joshua S. BogerDirectorSell10,400$124.23$1,291,992.00View SEC Filing  
11/2/2015Yuchun LeeDirectorSell1,125$126.19$141,963.75View SEC Filing  
10/28/2015Joshua S. BogerDirectorSell10,400$119.01$1,237,704.00View SEC Filing  
10/21/2015Joshua S. BogerDirectorSell10,400$108.82$1,131,728.00View SEC Filing  
10/14/2015Joshua S. BogerDirectorSell10,400$112.62$1,171,248.00View SEC Filing  
10/7/2015Joshua S. BogerDirectorSell10,400$109.61$1,139,944.00View SEC Filing  
10/2/2015Elaine UllianDirectorSell20,000$110.00$2,200,000.00View SEC Filing  
10/1/2015Stuart A. ArbuckleEVPSell12,417$104.71$1,300,184.07View SEC Filing  
10/1/2015Yuchun LeeDirectorSell1,125$104.64$117,720.00View SEC Filing  
9/30/2015Joshua S. BogerDirectorSell10,400$103.14$1,072,656.00View SEC Filing  
9/23/2015Joshua S. BogerDirectorSell10,400$111.89$1,163,656.00View SEC Filing  
9/16/2015Joshua S. BogerDirectorSell10,400$133.24$1,385,696.00View SEC Filing  
9/9/2015Joshua S. BogerDirectorSell10,400$131.41$1,366,664.00View SEC Filing  
9/4/2015Stuart A. ArbuckleEVPSell9,063$125.77$1,139,853.51View SEC Filing  
9/2/2015Joshua S. BogerDirectorSell10,400$125.85$1,308,840.00View SEC Filing  
9/1/2015Yuchun LeeDirectorSell1,125$125.40$141,075.00View SEC Filing  
8/26/2015Joshua S. BogerDirectorSell10,400$124.71$1,296,984.00View SEC Filing  
8/19/2015Joshua S. BogerDirectorSell10,400$139.93$1,455,272.00View SEC Filing  
8/12/2015Joshua S BogerDirectorSell10,400$135.83$1,412,632.00View SEC Filing  
7/22/2015Joshua S BogerDirectorSell10,400$130.92$1,361,568.00View SEC Filing  
7/15/2015Joshua S BogerDirectorSell12,200$133.98$1,634,556.00View SEC Filing  
7/13/2015Paul M SilvaSVPSell1,125$123.79$139,263.75View SEC Filing  
7/8/2015Joshua S BogerDirectorSell11,700$122.74$1,436,058.00View SEC Filing  
7/2/2015Jeffrey ChodakewitzCMOSell2,291$129.36$296,363.76View SEC Filing  
7/1/2015Joshua S BogerDirectorSell11,700$125.60$1,469,520.00View SEC Filing  
6/24/2015Joshua S BogerDirectorSell11,700$130.41$1,525,797.00View SEC Filing  
6/17/2015Joshua S BogerDirectorSell11,700$123.90$1,449,630.00View SEC Filing  
6/10/2015Joshua S BogerDirectorSell11,700$125.02$1,462,734.00View SEC Filing  
5/20/2015Joshua S BogerDirectorSell11,700$126.73$1,482,741.00View SEC Filing  
5/6/2015Joshua S BogerDirectorSell11,700$122.79$1,436,643.00View SEC Filing  
5/5/2015Paul M SilvaSVPSell4,101$123.68$507,211.68View SEC Filing  
4/29/2015Joshua S BogerDirectorSell11,700$124.59$1,457,703.00View SEC Filing  
4/27/2015Paul M SilvaSVPSell1,125$129.74$145,957.50View SEC Filing  
4/27/2015Stuart A ArbuckleEVPSell61,480$129.36$7,953,052.80View SEC Filing  
4/27/2015Terrence C KearneyDirectorSell68,125$129.11$8,795,618.75View SEC Filing  
4/22/2015Joshua S BogerDirectorSell11,700$132.46$1,549,782.00View SEC Filing  
4/15/2015Joshua S BogerDirectorSell11,700$129.25$1,512,225.00View SEC Filing  
4/13/2015Paul M SilvaSVPSell1,125$128.60$144,675.00View SEC Filing  
4/8/2015Joshua S BogerDirectorSell11,700$123.26$1,442,142.00View SEC Filing  
4/6/2015Margaret G McglynnDirectorSell12,500$118.36$1,479,500.00View SEC Filing  
4/2/2015Jeffrey ChodakewitzCMOSell2,291$115.50$264,610.50View SEC Filing  
4/1/2015Joshua S BogerDirectorSell11,700$115.87$1,355,679.00View SEC Filing  
3/25/2015Joshua S BogerDirectorSell11,700$120.76$1,412,892.00View SEC Filing  
3/23/2015Amit SachdevEVPSell17,083$132.28$2,259,739.24View SEC Filing  
3/23/2015Ian F SmithCFOSell6,042$125.67$759,298.14View SEC Filing  
3/23/2015Paul M SilvaSVPSell2,250$125.65$282,712.50View SEC Filing  
3/18/2015Amit SachdevEVPSell12,000$130.00$1,560,000.00View SEC Filing  
2/5/2015Paul M SilvaSVPSell1,688$109.75$185,258.00View SEC Filing  
2/4/2015Joshua S BogerDirectorSell5,700$108.81$620,217.00View SEC Filing  
2/3/2015Paul M SilvaSVPSell2,063$108.89$224,640.07View SEC Filing  
2/2/2015Jeffrey ChodakewitzCMOSell1,188$109.60$130,204.80View SEC Filing  
1/28/2015Joshua S BogerDirectorSell10,688$122.78$1,312,272.64View SEC Filing  
1/26/2015Paul M SilvaSVPSell1,125$125.62$141,322.50View SEC Filing  
1/21/2015Joshua S BogerDirectorSell10,500$125.08$1,313,340.00View SEC Filing  
1/14/2015Joshua S BogerDirectorSell10,500$120.16$1,261,680.00View SEC Filing  
1/9/2015Amit SachdevEVPSell12,000$125.00$1,500,000.00View SEC Filing  
1/9/2015Bruce I SachsDirectorSell9,861$125.04$1,233,019.44View SEC Filing  
1/7/2015Joshua S BogerDirectorSell10,500$119.32$1,252,860.00View SEC Filing  
1/2/2015Jeffrey ChodakewitzCMOSell2,291$122.54$280,739.14View SEC Filing  
12/22/2014Joshua S BogerDirectorSell10,500$117.65$1,235,325.00View SEC Filing  
12/17/2014Joshua S BogerDirectorSell10,500$110.66$1,161,930.00View SEC Filing  
12/15/2014Jeffrey M LeidenCEOSell50,017$114.97$5,750,454.49View SEC Filing  
12/12/2014Paul M SilvaSVPSell2,813$120.08$337,785.04View SEC Filing  
11/28/2014Amit SachdevEVPSell12,000$120.00$1,440,000.00View SEC Filing  
11/28/2014Bruce I SachsDirectorSell10,000$120.03$1,200,300.00View SEC Filing  
11/28/2014Paul M SilvaSVPSell8,164$119.85$978,455.40View SEC Filing  
11/26/2014Joshua S BogerDirectorSell10,500$114.54$1,202,670.00View SEC Filing  
11/6/2014Bruce I SachsDirectorSell9,900$115.21$1,140,579.00View SEC Filing  
11/5/2014Bruce I SachsDirectorSell30,100$112.62$3,389,862.00View SEC Filing  
11/3/2014Joshua S BogerDirectorSell127,411$112.20$14,295,514.20View SEC Filing  
10/29/2014Joshua S BogerDirectorSell10,500$109.44$1,149,120.00View SEC Filing  
10/28/2014Amit SachdevEVPSell12,000$115.00$1,380,000.00View SEC Filing  
10/28/2014David AltshulerDirectorSell2,000$114.75$229,500.00View SEC Filing  
10/28/2014Jeffrey ChodakewitzCMOSell3,438$115.00$395,370.00View SEC Filing  
10/27/2014Paul M SilvaSVPSell1,125$110.03$123,783.75View SEC Filing  
10/13/2014Paul M SilvaSVPSell1,125$107.89$121,376.25View SEC Filing  
10/7/2014Jeffrey ChodakewitzCMOSell3,436$104.26$358,237.36View SEC Filing  
10/6/2014David AltshulerDirectorSell1,405$109.75$154,198.75View SEC Filing  
10/1/2014Elaine UllianDirectorSell5,000$107.74$538,700.00View SEC Filing  
10/1/2014Stuart A ArbuckleEVPSell12,417$107.71$1,337,435.07View SEC Filing  
9/30/2014Amit SachdevSVPSell86,000$112.68$9,690,480.00View SEC Filing  
9/30/2014Ian F SmithCFOSell108,026$112.68$12,172,369.68View SEC Filing  
9/30/2014Jeffrey M LeidenCEOSell200,000$112.69$22,538,000.00View SEC Filing  
9/30/2014Kenneth L HortonEVPSell36,000$112.69$4,056,840.00View SEC Filing  
9/29/2014David AltshulerDirectorSell2,500$114.75$286,875.00View SEC Filing  
9/24/2014Joshua S BogerDirectorSell5,200$109.21$567,892.00View SEC Filing  
9/19/2014David AltshulerDirectorSell5,000$102.25$511,250.00View SEC Filing  
9/19/2014Paul M SilvaSVPSell25,408$99.85$2,536,988.80View SEC Filing  
9/19/2014Stuart A ArbuckleEVPSell55,521$100.00$5,552,100.00View SEC Filing  
9/17/2014Joshua S BogerDirectorSell5,200$93.62$486,824.00View SEC Filing  
9/10/2014Joshua S BogerDirectorSell5,200$94.42$490,984.00View SEC Filing  
9/5/2014David AltshulerDirectorSell2,500$94.75$236,875.00View SEC Filing  
9/3/2014Joshua S BogerDirectorSell5,200$92.79$482,508.00View SEC Filing  
8/27/2014Joshua S BogerDirectorSell5,200$93.31$485,212.00View SEC Filing  
8/20/2014Joshua S BogerDirectorSell5,200$91.51$475,852.00View SEC Filing  
8/13/2014Joshua S BogerDirectorSell5,200$88.00$457,600.00View SEC Filing  
8/6/2014Joshua S BogerDirectorSell5,200$86.54$450,008.00View SEC Filing  
7/31/2014David AltshulerDirectorSell5,000$89.59$447,950.00View SEC Filing  
7/31/2014Paul M SilvaSVPSell2,027$88.97$180,342.19View SEC Filing  
7/30/2014Joshua S BogerDirectorSell5,200$92.17$479,284.00View SEC Filing  
7/15/2014Wayne Joseph RileyDirectorSell4,800$96.65$463,920.00View SEC Filing  
7/1/2014Elaine UllianDirectorSell5,000$95.21$476,050.00View SEC Filing  
7/1/2014Kenneth L HortonEVPSell30,134$95.22$2,869,359.48View SEC Filing  
6/24/2014Megan E PaceSVPSell12,734$98.03$1,248,314.02View SEC Filing  
6/24/2014Wayne Joseph RileyDirectorSell15,000$98.03$1,470,450.00View SEC Filing  
6/16/2014Peter MuellerEVPSell7,500$68.31$512,325.00View SEC Filing  
6/9/2014Elaine UllianDirectorSell2,500$75.00$187,500.00View SEC Filing  
5/14/2014Peter MuellerEVPSell7,500$67.45$505,875.00View SEC Filing  
5/2/2014Megan PaceSVPSell1,000$67.62$67,620.00View SEC Filing  
4/15/2014Peter MuellerEVPSell7,500$61.63$462,225.00View SEC Filing  
4/9/2014Elaine UllianDirectorSell2,500$70.00$175,000.00View SEC Filing  
3/21/2014Bruce SachsDirectorSell8,700$74.59$648,933.00View SEC Filing  
3/17/2014Peter MuellerEVPSell7,500$78.29$587,175.00View SEC Filing  
2/7/2014Jeffrey LeidenCEOSell35,944$80.00$2,875,520.00View SEC Filing  
1/22/2014Bruce SachsDirectorSell8,300$84.47$701,101.00View SEC Filing  
1/21/2014Megan PaceSVPSell1,250$85.00$106,250.00View SEC Filing  
1/16/2014Jeffrey LeidenCEOSell45,000$80.00$3,600,000.00View SEC Filing  
1/15/2014Peter MuellerEVPSell7,500$78.67$590,025.00View SEC Filing  
12/23/2013Bruce SachsDirectorSell8,300$73.02$606,066.00View SEC Filing  
12/16/2013Peter MuellerEVPSell7,500$64.69$485,175.00View SEC Filing  
12/12/2013Jeffrey LeidenCEOSell9,834$65.48$643,930.32View SEC Filing  
12/12/2013Kenneth HortonEVPSell4,532$65.46$296,664.72View SEC Filing  
12/12/2013Megan PaceSVPSell5,083$65.48$332,834.84View SEC Filing  
12/4/2013Joshua BogerDirectorSell1,400$67.48$94,472.00View SEC Filing  
11/25/2013Joshua BogerDirectorSell1,400$66.89$93,646.00View SEC Filing  
11/20/2013Bruce SachsDirectorSell8,300$65.28$541,824.00View SEC Filing  
11/19/2013Joshua BogerDirectorSell1,400$62.31$87,234.00View SEC Filing  
11/5/2013Joshua BogerDirectorSell1,400$65.64$91,896.00View SEC Filing  
10/29/2013Joshua S BogerDirectorSell1,400$75.42$105,588.00View SEC Filing  
10/29/2013Thomas ConnollySVPSell1,688$75.04$126,667.52View SEC Filing  
10/24/2013Bruce I SachsDirectorSell8,300$77.06$639,598.00View SEC Filing  
10/23/2013Joshua S BogerDirectorSell1,400$76.77$107,478.00View SEC Filing  
10/16/2013Joshua S BogerDirectorSell1,400$75.41$105,574.00View SEC Filing  
10/15/2013Peter MuellerEVPSell7,500$73.25$549,375.00View SEC Filing  
10/14/2013Paul SilvaSVPSell1,593$71.87$114,488.91View SEC Filing  
10/9/2013Joshua BogerDirectorSell1,400$72.35$101,290.00View SEC Filing  
9/25/2013Joshua BogerDirectorSell1,400$74.72$104,608.00View SEC Filing  
9/18/2013Joshua BogerDirectorSell1,400$77.43$108,402.00View SEC Filing  
9/16/2013Peter MuellerEVPSell7,500$77.22$579,150.00View SEC Filing  
9/11/2013Joshua BogerDirectorSell1,400$79.61$111,454.00View SEC Filing  
9/4/2013Joshua BogerDirectorSell1,400$75.45$105,630.00View SEC Filing  
8/29/2013Bruce SachsDirectorSell8,300$77.19$640,677.00View SEC Filing  
8/28/2013Joshua BogerDirectorSell1,400$76.24$106,736.00View SEC Filing  
8/21/2013Joshua BogerDirectorSell1,400$76.96$107,744.00View SEC Filing  
8/15/2013Peter MuellerEVPSell7,500$77.41$580,575.00View SEC Filing  
8/14/2013Joshua BogerDirectorSell1,400$77.18$108,052.00View SEC Filing  
8/7/2013Joshua BogerDirectorSell1,400$77.84$108,976.00View SEC Filing  
8/5/2013Paul SilvaSVPSell3,001$78.90$236,778.90View SEC Filing  
7/31/2013Joshua S BogerDirectorSell1,400$80.89$113,246.00View SEC Filing  
7/29/2013Wayne Joseph RileyDirectorSell9,800$80.09$784,882.00View SEC Filing  
7/25/2013Paul M SilvaSVPSell1,125$86.49$97,301.25View SEC Filing  
7/24/2013Bruce I SachsDirectorSell8,300$85.50$709,650.00View SEC Filing  
7/19/2013Amit SachdevSVPSell22,250$88.69$1,973,352.50View SEC Filing  
7/18/2013Joshua S BogerDirectorSell1,400$86.12$120,568.00View SEC Filing  
7/16/2013Paul M SilvaSVPSell2,063$86.25$177,933.75View SEC Filing  
7/15/2013Christiana StamoulisSVPSell1,125$86.35$97,143.75View SEC Filing  
7/15/2013Peter MuellerEVPSell7,500$86.34$647,550.00View SEC Filing  
7/12/2013Megan E PaceSVPSell10,678$85.00$907,630.00View SEC Filing  
7/11/2013Joshua S BogerDirectorSell1,400$83.83$117,362.00View SEC Filing  
7/8/2013Kenneth L HortonEVPSell1,813$80.72$146,345.36View SEC Filing  
7/8/2013Megan E PaceSVPSell28,703$80.89$2,321,785.67View SEC Filing  
7/5/2013Christiana StamoulisSVPSell4,687$81.21$380,631.27View SEC Filing  
7/3/2013Joshua S BogerDirectorSell1,400$80.20$112,280.00View SEC Filing  
7/2/2013Peter MuellerEVPSell122,300$79.80$9,759,540.00View SEC Filing  
6/26/2013Joshua S BogerDirectorSell1,400$78.59$110,026.00View SEC Filing  
6/21/2013Bruce I SachsDirectorSell8,300$75.93$630,219.00View SEC Filing  
6/19/2013Joshua S BogerDirectorSell1,400$79.11$110,754.00View SEC Filing  
6/12/2013Joshua S BogerDirectorSell1,400$81.19$113,666.00View SEC Filing  
6/5/2013Joshua S BogerDirectorSell1,400$77.15$108,010.00View SEC Filing  
5/30/2013Joshua S BogerDirectorSell1,400$82.47$115,458.00View SEC Filing  
5/22/2013Joshua S BogerDirectorSell1,400$79.72$111,608.00View SEC Filing  
5/15/2013Joshua S BogerDirectorSell1,400$79.36$111,104.00View SEC Filing  
5/14/2013Bruce I SachsDirectorSell60,000$81.15$4,869,000.00View SEC Filing  
12/26/2012Joshua S BogerDirectorSell4,000$41.86$167,440.00View SEC Filing  
11/7/2012Margaret G McglynnDirectorBuy1,000$45.50$45,500.00View SEC Filing  
10/8/2012Ian F SmithCFOSell44,787$60.00$2,687,220.00View SEC Filing  
10/3/2012Joshua S BogerDirectorSell4,000$57.74$230,960.00View SEC Filing  
9/5/2012Joshua S BogerDirectorSell4,000$54.70$218,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Latest Headlines for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Source:
DateHeadline
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Lowered to "Strong Sell" at Vetr Inc.
www.americanbankingnews.com - May 28 at 7:38 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Vertex Pharmaceuticals Incorporated (VRTX) Will Announce Quarterly Sales of $485.53 Million
www.americanbankingnews.com - May 26 at 5:40 PM
americanbankingnews.com logo$485.53 Million in Sales Expected for Vertex Pharmaceuticals Incorporated (VRTX) This Quarter
www.americanbankingnews.com - May 26 at 5:38 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 26 at 8:51 AM
americanbankingnews.com logoZacks: Analysts Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Announce Earnings of $0.05 Per Share
www.americanbankingnews.com - May 24 at 1:28 PM
finance.yahoo.com logoVertex CEO: Our goal is to have one medicine for all cyst...
finance.yahoo.com - May 23 at 7:59 PM
finance.yahoo.com logoVertex Undergoes FTC Scrubbing for Deal on CF Treatment
finance.yahoo.com - May 22 at 7:37 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated Expected to Post Q2 2017 Earnings of $0.07 Per Share (VRTX)
www.americanbankingnews.com - May 22 at 7:06 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Earns Neutral Rating from Bank of America Corp
www.americanbankingnews.com - May 20 at 8:18 AM
americanbankingnews.com logoVertex Pharmaceuticals' (VRTX) "Overweight" Rating Reaffirmed at Morgan Stanley
www.americanbankingnews.com - May 20 at 8:18 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Earns Outperform Rating from JMP Securities
www.americanbankingnews.com - May 20 at 7:40 AM
americanbankingnews.com logoMaxim Group Analysts Give Vertex Pharmaceuticals Incorporated (VRTX) a $143.00 Price Target
www.americanbankingnews.com - May 19 at 8:29 PM
finance.yahoo.com logoVertex to Present at the UBS Healthcare Conference on May 23
finance.yahoo.com - May 19 at 1:40 PM
finance.yahoo.com logoVertex Awards 40 Scholarships Totaling $200,000 to People Living with Cystic Fibrosis and Their Immediate Family Members
finance.yahoo.com - May 19 at 1:40 PM
finance.yahoo.com logoVertex launches college scholarship program for cystic fibrosis patients, families
finance.yahoo.com - May 19 at 1:40 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) to Post FY2017 Earnings of $0.63 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - May 19 at 7:56 AM
finance.yahoo.com logoVertex boosts Kalydeco sales forecast after FDA approves for more patients
finance.yahoo.com - May 18 at 10:12 AM
finance.yahoo.com logoVertex Pharmaceuticals' Shares Pop in Afterhours Trading After FDA Approval while AstraZeneca Sinks on Clovis Upgrade
finance.yahoo.com - May 18 at 10:12 AM
finance.yahoo.com logoZacks.com featured highlights: Covanta Holding, PTC, Etsy, Vertex Pharmaceuticals and Live Nation Entertainment
finance.yahoo.com - May 18 at 10:12 AM
finance.yahoo.com logoFDA Approves KALYDECO® (ivacaftor) for More Than 900 People Ages 2 and Older with Cystic Fibrosis Who Have Certain Residual Function Mutations
finance.yahoo.com - May 17 at 10:12 PM
finance.yahoo.com logoVertex shares up more than 1% after FDA drug approval
finance.yahoo.com - May 17 at 10:12 PM
finance.yahoo.com logo5 Toxic Stocks to Steer Clear Of or Play Short Right Now
finance.yahoo.com - May 17 at 8:49 AM
streetinsider.com logoX-Chem, Vertex Pharma (VRTX) Enter Genetic Disease Collaboration
www.streetinsider.com - May 16 at 11:44 PM
fool.com logo3 Best Stocks in Personalized Medicine
www.fool.com - May 14 at 1:25 PM
finance.yahoo.com logoCWALT, Inc. Mortgage Pass-Through Certificates, Series 2006-45T1 -- Moody's Affirms Seven Classes of MSC 2016-UBS11
finance.yahoo.com - May 12 at 4:15 AM
fool.com logoHere's Why Vertex Pharmaceuticals Incorporated Gained 8% in April
www.fool.com - May 8 at 3:07 PM
seekingalpha.com logoVertex Q1 2017: Strong Signals - Seeking Alpha
seekingalpha.com - May 6 at 3:31 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) CMO Jeffrey Chodakewitz Sells 8,979 Shares
www.americanbankingnews.com - May 6 at 12:21 AM
americanbankingnews.com logoSomewhat Favorable Press Coverage Very Likely to Affect Vertex Pharmaceuticals (VRTX) Share Price
www.americanbankingnews.com - May 4 at 4:44 PM
americanbankingnews.com logoInsider Selling: Vertex Pharmaceuticals Incorporated (VRTX) CMO Sells 8,979 Shares of Stock
www.americanbankingnews.com - May 4 at 3:18 PM
finance.yahoo.com logoVertex Grants $1 Million to 15 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis
finance.yahoo.com - May 4 at 9:48 AM
americanbankingnews.com logo$486.2 Million in Sales Expected for Vertex Pharmaceuticals Incorporated (VRTX) This Quarter
www.americanbankingnews.com - May 3 at 3:16 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Vertex Pharmaceuticals Incorporated Cut by Oppenheimer Holdings (VRTX)
www.americanbankingnews.com - May 3 at 10:08 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Rating Increased to Buy at TheStreet
www.americanbankingnews.com - May 2 at 1:01 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - May 2 at 8:46 AM
americanbankingnews.com logoOppenheimer Holdings Inc. Reaffirms Hold Rating for Vertex Pharmaceuticals Incorporated (VRTX)
www.americanbankingnews.com - May 1 at 8:56 PM
americanbankingnews.com logoVertex Pharmaceuticals (VRTX) Receiving Somewhat Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - May 1 at 4:10 PM
fool.com logoVertex Pharmaceuticals Incorporated: Solid Sales, Prepping for Next Generation
www.fool.com - May 1 at 3:23 PM
americanbankingnews.com logo Analysts Anticipate Vertex Pharmaceuticals Incorporated (VRTX) Will Post Earnings of $0.14 Per Share
www.americanbankingnews.com - May 1 at 1:52 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 1 at 11:58 AM
fool.com logo3 Top Biotech Stocks to Buy Now
www.fool.com - April 29 at 12:40 PM
rttnews.com logoVertex Pharmaceuticals Inc. Q1 Profit Advances 352%
www.rttnews.com - April 29 at 2:12 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Earns Hold Rating from Needham & Company LLC
www.americanbankingnews.com - April 29 at 1:01 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) CEO Sells $18,785,400.00 in Stock
www.americanbankingnews.com - April 29 at 12:36 AM
americanbankingnews.com logoVertex Pharmaceuticals' (VRTX) Outperform Rating Reiterated at Credit Suisse Group AG
www.americanbankingnews.com - April 28 at 11:31 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Receives "Outperform" Rating from Robert W. Baird
www.americanbankingnews.com - April 28 at 10:42 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Posts Earnings Results, Beats Estimates By $0.09 EPS
www.americanbankingnews.com - April 28 at 4:48 PM
americanbankingnews.com logoPositive News Coverage Very Likely to Affect Vertex Pharmaceuticals (VRTX) Share Price
www.americanbankingnews.com - April 28 at 1:36 PM
seekingalpha.com logoVertex Pharmaceuticals (VRTX) Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - April 28 at 10:33 AM
finance.yahoo.com logoEdited Transcript of VRTX earnings conference call or presentation 27-Apr-17 8:30pm GMT
finance.yahoo.com - April 28 at 10:32 AM

Social

Chart

Vertex Pharmaceuticals Incorporated (VRTX) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff